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Patients attended by palliative care teams: are they always comparable populations? To answer this question we
have compared the basic epidemiological characteristics of patients attended by home palliative care teams (HPCT)
in two autonomous regions of Spain.
We carried out a coordinated analytical, observational and prospective study in two Spanish autonomous regions:
Aragon and Catalonia. Data were kept during each home care visit according to patients' needs. Inclusion criteria
were: advanced cancer, over 18 years old and first contact with a HPCT. The recruitment period was 6 months.
Variables included were: Survival time (days), age, sex, primary disease and extension, place of residence. Functional
and cognitive state, and co-morbidity. 10 signs/symptoms: asthenia, anorexia, cachexia, dysphagia, xerostomy,
dyspnoea, oedemas, level of consciousness, presence of delirium, presence of pressure ulcers and some treatment
data. Others variables considered were: responsible team, origin, destination when discharge, date and place of
death, number of visits made and duration of monitoring. We developed a comparison between groups by Chi-
squared test or the non-parametric Mann–Whitney U test and a survival analysis by Kaplan-Meier curves and the
logrank test to determine differences between factors. The SPSS version 15.0 software package was used.
698 patients were included, 56.2% from Aragon and 43.8% from Catalonia. 60.3% were males, without differences
between the regions. Characteristics relative to age, sex, place of residence and extension of oncological diseases
were similar for both groups. We found significant differences between the two populations relative to survival
time, co-morbidity, functional state, presence and intensity of a number of symptoms and the treatments, patient
monitoring and the their destination after discharge.
We can conclude that palliative care teams cover different profiles of patients with regard to their co-morbidity,
functional, cognitive and symptomatic states. It must be pointed that the organization of palliative care services
and their experience appears to condition the profile of patients they attend. There is a need of consensus on the
basic descriptors for palliative care patients in order to ensure that results will be comparable.Introduction
Cicely Saunders started the modern hospice movement
in 1967 with the founding of St Christopher’s Hospice in
London (Clark 2000). The development of palliative care
in Europe and in Spain has progressed slowly since then
(SECPAL 2012; Rocafort 2007).
The European Association for Palliative Care (EAPC)
carried out a study on the development of palliative care* Correspondence: mnabal.lleida.ics@gencat.cat
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in any medium, provided the original work is pin European countries. The Task Force on the Develop-
ment of Palliative Care in Europe, headed by Carlos
Centeno and David Clark, published its results in the
EAPC Atlas Of Palliative Care In Europe (Centeno et al.
2007). For the first time it offered reliable infor-
mation that enabled the state of palliative care ser-
vices in the different European countries to be compared
(Rocafort & Centeno 2008). This study illustrated the ex-
istence of a number of common organizational struc-
tures and great diversity in the development of different
types of programmes and in the provision of services.
These differences are, at least, partly related to the dif-
ferent ways of interpreting the underlying concepts and
terms in palliative medicine. In order to make validOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Nabal et al. SpringerPlus 2013, 2:177 Page 2 of 7
http://www.springerplus.com/content/2/1/177comparisons, it is necessary to develop a common lan-
guage (von Guten 2007).
With this aim, the EAPC published its suggestions for
use in Europe of a common terminology following a
process of consensus with national associations. Quality
standards will be defined based on this terminology of
consensus. Guidelines for regulations and standards are
necessary not only for health care professionals working
in the field of palliative care, but also for those entrusted
with taking health-related decisions, who are responsible
for providing patients with suitable access to palliative
care (Radbruch et al. 2009; Radbruch et al. 2010).
The differences that exist in the organizational frame-
work are transferred to the clinical framework (Currow
et al. 2009). Do palliative care teams attend the same
type of patients? Can comparisons be made between pa-
tients in different regions of the same country or be-
tween those of different countries? Does the degree of
development of palliative care services influence the
characteristics of the patients they attend? There are
currently no clear answers to these questions, and al-
though a number of initiatives exist that are trying to
reach consensus on the minimum information required
to describe some symptoms, there is as yet no standard-
ized practice (Jack et al. 2009; 2010; Knudsen et al. 2009).
This fact has great transcendence in research and clinical
practice. If populations are not homogeneous, the results
of multicentric studies may not be completely conclusive.
Will we be able to transfer the results of research car-
ried out in other countries to our patients without local
validation?
Therefore, it would seem necessary to seek consensus
on the basic descriptors that characterize patient sam-
ples, simultaneously with the carrying out of studies that
verify similarities and differences in groups of patients
attended by different teams in different geographical or
cultural areas and/or different countries.
Catalonia and Aragon are two neighbouring autono-
mous regions with uneven trajectories in palliative care.
Catalonia is an autonomous region with an area of
31,895 km2 located in the north-east of the Iberian
Peninsula. It has a population of 7,364,079, which ac-
counts for 15.9% of Spain’s total. The demographic distri-
bution is uneven, oscillating between 1.3 and 17,725
inhabitants per km2. Palliative care services in Catalonia
started in 1987 (Centeno et al. 2000) and the regional gov-
ernment of Catalonia produced a pilot plan for the devel-
opment of palliative care services in 1990 in partnership
with the World Health Organization (Sanz 1999; Porta
Sales & Albo 1998). This institutional support led to the
development of a global palliative care network (Gómez-
Batiste et al. 1992): 134 specialist palliative care teams, 59
of which act as home care teams, 28 as hospital support
teams and 33 as PCUs in university teaching hospitals andmedium-term and long-term care facilities. There are also
6 psychosocial teams and 2 centres that act as observator-
ies (Gómez-Batiste et al. 2007).
The autonomous region of Aragon is also located in
the north-east of the Iberian Peninsula. It is the fourth
largest of Spain’s autonomous regions in size, with an
area of 47,720 km2; however, its low population density
of barely 25 inhabitants per km2 is the second lowest in
the country. The population of the region does not ex-
ceed 1,200,000, although its distribution is closely as-
sociated with the location of industry and services.
Practically half of the population of Aragon lives in its
capital, Zaragoza. Palliative care services began in
Aragon in 1990, as the result of the concern felt by a
group of primary care practitioners who created the first
palliative care protocol in a health centre (Torrubia et al.
1990). The first publicly financed home care support
team was set up in 1999 (Instituto Nacional de la Salud
1999). The approval of the National Palliative Care Plan
in 2000 fostered the progressive development of new re-
sources (Gobierno de Aragón 2003). Aragon currently
has 11 specialist palliative care teams, 8 of which act as
home care teams and 1 as a hospital support team; 1
PCU in a medium and long-term care facility; and 1 psy-
chosocial team 2.
A study carried out by the Spanish Ministry of Health
established that Catalonia was an autonomous region
with an equitable distribution of resources and access
times for both home and hospital palliative care. How-
ever, Aragon does not have an equitable distribution of
resources or isochronal intervention, despite great ef-
forts made to provide home care services in rural areas
(Herrera et al. 2012).
This study was developed with the aim of establishing
similarities and differences between patients attended by
palliative care teams in two Spanish autonomous regions
as part of a broader study on prognostic tools in pallia-
tive care (Nabal et al. 2010a; Nabal et al. 2010b).Material and methods
This study forms part of a broader study for the vali-
dation and improvement of prognostic models in pal-
liative care. It is therefore a coordinated analytical,
observational and prospective study. The recruitment
period was 6 months, with monitoring until the patients’
death or 180 days.
The data collected came from all visits made by each
palliative care team according to the needs of each
patient.
The study was carried out in Aragon and Catalonia.
The work was carried out by 8 home care support teams
(ESAD) in Aragon and by 5 home care support teams
(PADES) in Catalonia.
Catalonia
43.8%
Aragon
56.2%
Figure 1 Sample distribution by region.
Table 1 Clinical and demographic characteristics of
patients (n = 698)
TOTAL ARAGON CATALONIA p-valueb
(n = 698) (n = 392) (n = 306)
Age (years) a 73.7 ± 12 74.9 ± 11 72.1 ± 13 0.002
Gender, male (%) 60.3 59.6 61.1 0.694
Urban (%) 69.8 66.8 73.7 0.049
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The sample was calculated according to published rec-
ommendations of 10–15 events for each dichotomous
variable, and 10–15 (n-1) for each categorical variable.
Inclusion criteria: patients with advanced cancer, over
18 years of age and first contact with a palliative home
care team.
The analysed variables were:
– Survival time (days).
– General information: age, sex, primary disease and
extension, place of residence.
– Clinical information: functional state (Karnofsky,
Barthel, ECOG), cognitive state (Pfeiffer), co-
morbidity (Charlson) and 10 signs/symptoms rated
according to their intensity by a categorical scale
between 0 a 3 where 0 was non, 1 was slight, 2 was
moderate and 3 was severe. The sings and
symptoms assessed were: asthenia, anorexia,
cachexia, dysphagia, dry mouth, dyspnoea, oedemas,
level of consciousness, presence of delirium,
presence of pressure ulcers.
– Treatment-related information: corticosteroids,
subcutaneous butterfly needle.
– Activity information: responsible team, origin,
destination when discharge, date and place of death,
number of visits made and duration of monitoring.
The categorical variables are expressed as a percentage
and the quantitative variables as mean ± standard devi-
ation. The comparison between groups was made by
means of the Chi-squared test or the non-parametric
Mann–Whitney U test according to the variable type.
Survival analysis was made using with Kaplan-Meier
curves and the logrank test to determine differences
between factors. Statistical significance was defined as
p < 0.05.
The SPSS version 15.0 software package was used.Metastasis (%) 62.5 64.8 59.5 0.150
Neoplasm (%) 0.013
Head and Neck 3.2 2.6 3.9
CNS 25.3 25.1 25.5
Upper Digestive
tract
17.7 20.1 14.7
Low Digestive tract 19.9 17.7 22.5
Lung 15.6 16.1 15.0
Genitourinary 6.9 7.4 6.2
Breast 1.8 0.5 3.3
Haematological 2.3 3.7 0.7
Others 3.8 3.7 3.9
Unknown 3.5 2.9 4.2
a: mean ± standard deviation; b: median (interquartile range). b: Comparison
between groups; p determined by the χ2 test for Comparison of proportions
or Mann–Whitney test for continuous variables.Results
698 patients were included, of which 56.2% were from
Aragon and 43.8% were from Catalonia. 60.3% were
males, without differences between the regions (Figure 1).
Table 1 shows the general clinical and demographic
characteristics of the patients. The sample did not show
significant differences by age, gender, place of living or
cancer type and stage. The clinical characteristics rela-
tive to functional and cognitive state, co-morbidity and
treatment can be seen in Table 2. It can be pointed that
performance status was better for those patients treated
in Catalonia by any performance status scale used. No
differences were found on cognitive status or co – mor-
bidity. The use of corticoids and subcutaneous butterflywas greater in Aragon, which may be related to the
worse performance status of this sample.
Table 3 shows the similarities and differences related
to signs and symptoms. As can be seen globally, the pro-
portion of patients suffering from anorexia, asthenia, dry
mouth, dyspnoea or dysphagia did not differ between
both places of care; although the highest levels of ano-
rexia, asthenia and dry mouth were more frequent in
Table 2 Functional and cognitive state, co-morbidity and
treatment (n = 698)
TOTAL ARAGON CATALONIA p-valueb
(n = 698) (n = 392) (n = 306)
KARNOFSKYa 51.8 ± 14 48.8 ± 15 55.7 ± 13 < 0.001
ECOGa 2.5 ± 1 2.7 ± 1 2.2 ± 1 < 0.001
BARTHELa 56.2 ± 33 49.5 ± 34 64.9 ± 30 < 0.001
PFEIFFERa 2.6 ± 4 2.9 ± 4 2.1 ± 4 0.094
CHARLSONa 5.8 ± 2 5.9 ± 2 5.6 ± 2 0.020
Corticosteroids (%) 37.5 29.8 47.4 < 0.001
SC Butterfly needle (%) 8.3 9.9 6.2 0.076
SC: Subcutaneous. a: mean ± standard deviation. b: Comparison between groups;
p determined by the χ2 test for Comparison of proportions or Mann–Whitney test
for continuous variables.
Table 3 Comparative analysis of symptoms (n = 698)
TOTAL ARAGON CATALONIA p-valuea
(n = 698) (n = 392) (n = 306)
Anorexia (%) 0.010
0 29.1 25.8 33.3
1 33.0 35.2 30.1
2 27.8 26.3 29.7
3 10.2 12.8 6.9
Asthenia (%) 0.114
0 16.5 16.4 16.7
1 31.3 29.5 33.7
2 32.8 31.5 34.3
3 19.4 22.6 15.4
Dry mouth (%) 0.246
0 41.4 41.2 41.6
1 34.6 32.2 37.7
2 17.5 19.7 14.8
3 6.5 6.9 5.9
Oedemas (%) 0.366
0 66.8 64.3 69.9
1 21.1 23.0 18.6
2 9.6 9.7 9.5
3 2.6 3.1 2.0
Consciousness (%) 0.886
0 88.7 89.0 88.2
1 6.7 6.1 7.5
2 3.2 3.3 2.9
3 1.4 1.5 1.3
Dyspnoea (%) 0.106
0 59.3 63.3 54.2
1 18.3 16.3 20.9
2 12.6 10.5 15.4
3 7.7 7.9 7.5
4 2.0 2.0 2.0
Dysphagia (%) 0.788
0 76.3 76.7 75.7
1 13.5 12.5 14.8
2 5.5 6.1 4.6
3 2.4 2.6 2.3
4 2.3 2.0 2.6
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conscience, were worse in Aragon but higher levels of
cachexia and pressure sores were more frequent in
Catalonia.
Finally, Table 4 shows the results for activity: respon-
sible team, origin, destination after hospital discharge,
date and place of death, number of visits made and du-
ration of monitoring. The number of patients treated by
palliative home care teams coming form general practi-
tioners or oncologist were greater in Aragon. On the
other hand, the number of patients discharged form pal-
liative care units to home palliative care teams was
higher in Catalonia, which may be related to the greater
number of PCU in this region. In the same way, the time
of follow up was longer in Catalonia. It must be pointed
out that patients treated in Aragon got off PC program
more than twice comparing with Catalonia.
Regarding the place of death, significant differences
were seen (p < 0.001). In Aragon the proportion of pa-
tients dead at home was greater (78 vs. 41%). On the
other hand, comparing the number of patients died at
PCU, this was greater in Catalonia (44 vs. 4%). No sig-
nificant differences were fond on the percentage of pa-
tients who died at acute hospitals between Aragon and
Catalonia (18 vs. 15%).
The survival time for both groups is expressed as
Kaplan-Meier curves in Figure 2 and was greater in
Catalonia.Cachexia (%) 0.268
0 52.9 56.1 48.9
1 28.4 26.0 31.5
2 13.3 13.0 13.8
3 5.3 4.8 5.9
Pressure sores (%) 0.117
0 90.7 88.9 93.0
1 6.9 8.5 4.7Discussion
This work illustrates the differences that exist in the cha-
racteristics of patients attended by home palliative care
teams in two different neighbouring regions in Spain. This
work is part of broader research that has the aim of
establishing the prognostic values of different symptoms
and the impact of repeated measurements on prognostic
models (Christakis & Iwashyna 2000; Passik et al. 2004).
Table 3 Comparative analysis of symptoms (n = 698)
(Continued)
2 1.3 1.8 0.7
3 0.6 0.5 0.7
Delirium (%) 4.6 5.6 3.3 0.142
aComparison between groups; p determined by the χ2 test.
Logrank test = 9.9 (p <0.02) 
Aragon
Catalonia
Aragon censored
Catalonia censored
Figure 2 Survival curves.
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dology that is not specially designed to establish simila-
rities and differences between these two population
groups, the findings obtained invite the reflection. The
study involves a broad sample of patients included con-
secutively. Recruitment was the result of home palliative
care services provided by the 13 participating teams.
The breadth of the inclusion criteria may justify part of
the epidemiological variability, but it does not explain
the differences that exist between the two regions. Ne-
vertheless, following along the lines of the work by
Currow et al. (2009), our research compiled parameters
of co-morbidity, primary disease and functional state, to-
gether with basic information on age and sex. However,
information related to psychosocial factors were not
considered, although the fact that patients remained in
their homes is already an indirect factor for requiring
basic support.
The patients involved were treated by palliative care
teams and had different survival times, a difference that
has been maintained over time in favour of Catalonia.
This may be explained by the greater development of
palliative care services in Catalonia, which began in
1990. The intervention by the Catalan teams seems to
be made earlier during the course of the disease, ensu-
ring more prolonged monitoring. This coincides withTable 4 Palliative care team activity (n = 698)
TOTAL ARAGON CATALONIA p-valueb
(n = 698) (n = 392) (n = 306)
Point of origin 0.002
Primary care 55.0 56.6 52.9
Oncology 22.6 25.0 19.6
Other departments 13.3 11.2 16.0
PCU 4.6 2.0 7.8
No. of visitsa 7 ± 4 5 ± 3 8 ± 5 < 0.001
Duration on programmea
(days)
65 ± 64 51 ± 55 77 ± 68 < 0.001
Situation (%) < 0.001
Death 74.4 72.4 76.8
Off programme 16.9 22.4 9.8
Alive 8.7 5.1 6.2
a: mean ± standard deviation; b: Comparison between groups; p determined by
the χ2 test for Comparison of proportions or Mann–Whitney test for
continuous variables.Currow et al. (2009), who assert that there might be
factors related to professional training and staffing that
influence patient profiles and which should be descri-
bed in order for results to be correctly interpreted
(Christakis & Iwashyna 2000). Passik et al. (2004) and
Rowett et al. (2009) draw attention to the fact that
health policy choices influence access to and the devel-
opment of palliative care services.The fact that health
policies are the responsibility of each autonomous region
may contribute to enhance the differences. As Christakis
points out, in many cases, access to palliative care ser-
vices is very late and the differences in survival times are
seen to be influenced by the primary disease but also by
the type of care to which they have access (Christakis &
Escarce 1996).
In contrast, the Aragonese population presented a
higher mean age, worse functional and cognitive states,
and higher rates of co-morbidity, although the diffe-
rences in this last parameter were not significant. These
data may explain the different survival times for the two
groups, given that many authors have correlated func-
tional state and co-morbidity with a poor prognosis
(Nabal et al. 2002). The existence of differences in sur-
vival times of cancer patients between countries has
been extensively discussed and seems to bear relation to
early diagnosis and the treatments offered (Coleman
et al. 2011).
In relation to symptoms, we identified that the preva-
lence and intensity of symptoms such as asthenia, cach-
exia and dyspnoea is higher in Catalonia in comparison
with Aragon, which presents higher frequencies and
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Taking into account that mortality is higher in Aragon,
the data gathered leads to the suspicion that patients
suffering from dyspnoea or intense caquexia leave their
homes or do not return to them. The profile of patients
attended in Aragon seems to be less complex on the
whole from a clinical perspective, but with greater diffi-
culty for access to and attention by palliative care ser-
vices due to their greater geographical dispersion and
the lower number of specialist resources.
Intervention for both groups is made mostly at the re-
quest of a general practitioner, particularly in the case of
the Catalan population where more than half of the
intervention requests came from primary care. It seems
that the integration of home palliative care support
teams is more consolidated in Catalonia, and it is more
common to find general practitioners and home pallia-
tive care teams working together. Among the other
points of origin, it is of note that patients in the Catalan
group come from PCUs, whilst this group is much re-
duced in Aragon. This could be explained by the fact
that there is a support network in Catalonia that covers
almost the entire region at all levels of health care, while
Aragon has a model based on home care with few long-
stay PCUs that is mostly based in large urban areas
(Nabal et al. 2010b).
The patients in our sample from Aragon are less com-
monly located in an urban area, which means that their ac-
cess to long-stay units is more difficult and less frequent.
There has been growing interest in recent years in de-
scribing the organization of palliative care services in
different countries (Centeno et al. 2007; Burt et al. 2010;
Lynch et al. 2009; Ferris et al. 2009), although popula-
tions treated by palliative care teams have not been so
accurately compared. Most of the scientific works pub-
lished in this regard dedicate a section to the description
of the population covered by them, but there is no con-
sensus on the minimum essential data, making it diffi-
cult to compare the results of such research, or else we
run the risk of extrapolating results that are applicable
to us to any profile of patient treated by palliative care
teams (Currow et al. 2009).
In fact, these findings can be extended to the description
of the main symptoms treated in palliative care. The ab-
sence of consensus, on the basic descriptors for pain,
makes comparison between studies difficult. The system-
atic reviews concerning cachexia and pain demonstrate that
the absence of shared definitions and the different idiom-
atic connotations attached to descriptors make difficult to
generalize the results of research (Knudsen et al. 2009;
Fearon et al. 2011; Blue et al. 2011).
There is currently an EAPC research network initiative
in progress, in collaboration with the PRISMA project
and the European Palliative Care Research Centre (PRC)in Trondheim, Norway, to reach consensus on the mini-
mum set of data capable to describe the population re-
ceiving palliative care. This is currently being developed
using the Delphi method.
Our work corroborates the need for international con-
sensus in which descriptors for co-morbidity, cognitive
and functional state, and the presence or absence of the
most prevalent symptoms are contemplated in addition
to personal details and particulars of the disease. These
data should possibly be complemented with information
on the emotional and social/family sphere of patients
and the intervention setting. We will only be able to de-
fine homogeneous groups and compare the results of
our research with a more detailed profile of our patients.
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